ClinicalTrials.gg
CompletedNCT06752590Updated Jul 7, 2026

A Clinical Study of ONO-1110 in Patients With Fibromyalgia

A Phase 2 interventional study of ONO-1110 and Placebo in Fibromyalgia, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 30 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Fibromyalgia

02

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • ONO-1110
  • ONO-1110-05
  • Fibromyalgia
03

In context

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

This study's enrollment of 175 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese (both sexes)
  • Outpatient
  • Patients who are considered capable of understanding the study procedures and completing the pain diary and questionnaires appropriately by the investigator (sub-investigator)
  • Patients who meet the American College of Rheumatology Fibromyalgia Criteria

Exclusion criteria

Exclusion Criteria:

  • Patients with inflammatory arthritis, infectious arthritis, or disease
  • Patients with pain other than FM that may affect assessments in this study
  • Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
  • Patients with a past history of or concurrent malignant tumor within 3 years
  • Patients who are pregnant, nursing, or possibly pregnant, or intending to become pregnant during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    ONO-1110

    ONO-1110 tablets once a day

    Drug: ONO-1110

  • Placebo comparator
    Placebo

    Placebo tablets once daily

    Drug: Placebo

Interventions

  • ONO-1110 tablets once a day

  • DrugPlacebo

    Placebo tablets once daily

06

What researchers measure

Primary outcomes

  1. Change in weekly mean of average pain score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  2. Adverse events

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Change in weekly mean of average pain score from baseline in each week

    Time frame: Up to 16 weeks

  2. 30%- and 50%-responder rates based on the weekly mean of average pain score

    proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively

    Time frame: Up to 16 weeks

  3. Change in weekly mean of worst pain score from baseline to each week

    Time frame: Up to 16 weeks

  4. 30%- and 50%-responder rates based on the weekly mean of worst pain score

    proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively

    Time frame: Up to 16 weeks

  5. Change in WPI and SSS score of 2016 Revised FM Diagnostic Criteria by ACR from baseline

    Time frame: Up to 16 weeks

  6. Change in Japanese version of the Revised Fibromyalgia Impact Questionnaire (JFIQR) score from baseline

    Time frame: Up to 16 weeks

  7. Change in Patient Global Impression of Change (PGIC) score from baseline

    Time frame: Up to 16 weeks

  8. Change in Hospital Anxiety and Depression Scale (HADS) score from baseline

    Time frame: Up to 16 weeks

  9. Change in Medical Outcomes Study Sleep Scale (MOS-Sleep Scale) score from baseline

    Time frame: Up to 16 weeks

  10. Plasma ONO-1110 concentrations

    Time frame: Up to 16 weeks

07

Study locations

30 sites
  • Aichi Medical University Hospital
    Nagakute, Aichi-ken, Japan
  • Kimura Clinic
    Nagoya, Aichi-ken, Japan
  • National Hospital Organization Shimoshizu National Hospital
    Yotsukaidō, Chiba, Japan
  • Ai Sakura Clinic
    Fukuoka, Fukuoka, Japan
  • Sapporo City General Hospital
    Sapporo, Hokkaido, Japan
  • Mayflower Hospital
    Katō, Hyōgo, Japan
  • Shirasawa Orthopedic Clinic
    Morioka, Iwate, Japan
  • Kokorotoitami Clinic
    Kawasaki, Kanagawa, Japan
  • Women's Clinic Luna
    Yokohama, Kanagawa, Japan
  • Junwakai Memorial Hospital
    Miyazaki, Miyazaki, Japan
  • Miyashita Rheumatology Clinic
    Ōmura, Nagasaki, Japan
  • Medical Corporation Fujigaki Clinic
    Ōita, Oita Prefecture, Japan
  • Japanese Red Cross Okayama Hospital
    Okayama, Okayama-ken, Japan
  • Hayaishi Hospital
    Osaka, Osaka, Japan
  • Morimoto Clinic
    Osaka, Osaka, Japan
  • Shizuoka Rehab Pain Clinic
    Shizuoka, Shizuoka, Japan
  • Fukuwa Clinic
    Tokyo, Tokyo, Japan
  • Ginza Neurological Clinic
    Tokyo, Tokyo, Japan
  • Himenotomomi Clinic
    Tokyo, Tokyo, Japan
  • Ikebukuro Internal Medicine
    Tokyo, Tokyo, Japan
  • Juntendo Tokyo Koto Geriatric Medical Center
    Tokyo, Tokyo, Japan
  • Juntendo University Hospital
    Tokyo, Tokyo, Japan
  • Juntendo University Nerima Hospital
    Tokyo, Tokyo, Japan
  • Nihonbashi Medical
    Tokyo, Tokyo, Japan
  • Nishiogi Pain Clinic
    Tokyo, Tokyo, Japan
  • Sanno Hospital
    Tokyo, Tokyo, Japan
  • Tokyo-Eki Center-Building Clinic
    Tokyo, Tokyo, Japan
  • Toyama University Hospital
    Toyama, Toyama, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Yakushinkai Healthcare Association Kandasudacho Dermatology
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2026, 14 months.

Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2024
First posted
Dec 30, 2024
StartActual
Mar 26, 2025
Primary completionActual
May 30, 2026
CompletionActual
May 30, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752590
Responsible party
Sponsor
First posted
Dec 30, 2024
Start date
Mar 26, 2025
Primary completion
May 30, 2026
Completion
May 30, 2026
Last update
Jul 7, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-1110

Start the discussion